Abstract
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Receptor antagonists prevent attachment of gp120 to the receptor or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. Enfuvirtide (T20, Fuzeon) is a peptide based on the gp41 sequence and is the only approved fusion inhibitor. It prevents membrane fusion by competitively binding to gp41 and blocking the formation of the post-fusion structure. New generations of T20-like peptides have been developed with improved potency and stability. Besides T20 and derivatives, other fusion inhibitors have been developed that target different domains of gp41. Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens.
Keywords: HIV, virus entry, antiviral peptide, fusion inhibitors, enfuvirtide, T20, VIRIP, resistance, HIV-1, envelope glycoprotein complex, human immunodeficiency virus type 1, gp41, gp120, Fuzeon, acquired immunodeficiency syndrome, Highly Active Antiretroviral Therapy (HAART), reverse transcriptase (RT), nucleoside analogue, non-nucleoside RT inhibitors, DNA strand elongation, zidovudine, stavudine, thymidine, didanosine, abacavir, guanine, viral Gag, Gag-Pol precursor, Saquinavir, ritonavir, indinavir, integrase, Maraviroc, BMS-378806, PRO542, immunoglobulin, vicriviroc, coronaviridae, TORO phase III study, HXB2 isolate, S138A, N126K, Cyclic depsipeptides, Siliquaria spongia mirabilis
Current Pharmaceutical Design
Title: Inhibition of HIV-1 by Fusion Inhibitors
Volume: 16 Issue: 33
Author(s): Dirk Eggink, Ben Berkhout and Rogier W. Sanders
Affiliation:
Keywords: HIV, virus entry, antiviral peptide, fusion inhibitors, enfuvirtide, T20, VIRIP, resistance, HIV-1, envelope glycoprotein complex, human immunodeficiency virus type 1, gp41, gp120, Fuzeon, acquired immunodeficiency syndrome, Highly Active Antiretroviral Therapy (HAART), reverse transcriptase (RT), nucleoside analogue, non-nucleoside RT inhibitors, DNA strand elongation, zidovudine, stavudine, thymidine, didanosine, abacavir, guanine, viral Gag, Gag-Pol precursor, Saquinavir, ritonavir, indinavir, integrase, Maraviroc, BMS-378806, PRO542, immunoglobulin, vicriviroc, coronaviridae, TORO phase III study, HXB2 isolate, S138A, N126K, Cyclic depsipeptides, Siliquaria spongia mirabilis
Abstract: The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Receptor antagonists prevent attachment of gp120 to the receptor or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. Enfuvirtide (T20, Fuzeon) is a peptide based on the gp41 sequence and is the only approved fusion inhibitor. It prevents membrane fusion by competitively binding to gp41 and blocking the formation of the post-fusion structure. New generations of T20-like peptides have been developed with improved potency and stability. Besides T20 and derivatives, other fusion inhibitors have been developed that target different domains of gp41. Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens.
Export Options
About this article
Cite this article as:
Eggink Dirk, Berkhout Ben and W. Sanders Rogier, Inhibition of HIV-1 by Fusion Inhibitors, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079218
DOI https://dx.doi.org/10.2174/138161210794079218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes
Current Drug Metabolism Visceral Adipose Tissue and Atherosclerosis
Current Vascular Pharmacology The Epigenomic Viewpoint on Cellular Differentiation of Myeloid Progenitor Cells as it Pertains to Leukemogenesis
Current Genomics Role of Androgens in Womens Sexual Function & Dysfunction: What Have We Learned in Six Decades?
Current Women`s Health Reviews Near Infrared Optical Technologies to Illuminate the Status of the Neonatal Brain
Current Pediatric Reviews Exploring the Nutraceutical Potential of Polyphenols from Black, Green and White Tea Infusions – An Overview
Current Pharmaceutical Biotechnology Herbal Medicine in the Treatment of Epilepsy
Current Drug Targets The 2009 Influenza Pandemic: Promising Lessons For Antiviral Therapy For Future Outbreaks
Current Medicinal Chemistry RNA Interference: New Therapeutics in Allergic Diseases
Current Gene Therapy Simultaneous Determination of Saponins and Lignans in Rat Plasma by UPLC- MS/MS and its Application to a Pharmacokinetic Study of Shenqi Jiangtang Granule
Current Drug Metabolism The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option
Current Topics in Medicinal Chemistry The Role of Insulin Resistance and Hyperinsulinemia in Cancer Causation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology Cellular Mechanisms that Edit the Immunopeptidome
Current Proteomics Cytokines in HIV-Infection - Inflammatory Damage or Therapeutic Potential?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology